Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

Clinical Trials

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Halting the progression of chronic kidney disease: an audit of the use of RAASi and SGLT2i.

Irish medical journal·2025

Same author

Glomerulonephritis with Positive Anti-Glomerular Basement Membrane Antibodies following COVID-19 Vaccine.

Irish medical journal·2025

Same author

The 2018 Revised FDA Guidance for Early Alzheimer's Disease: Establishing the Meaningfulness of Treatment Effects.

The journal of prevention of Alzheimer's disease·2019

Same author

The Prevalence and Management of Metabolic Acidosis of Chronic Kidney Disease

Irish medical journal·2019

Same author

Assessing the effects of intra-granule precipitation in a full-scale industrial anaerobic digester.

Water science and technology : a journal of the International Association on Water Pollution Research·2019

Same author

Evaluation of anaerobic digestion post-treatment options using an integrated model-based approach.

Water research·2019

Search research articles

Related Experiment Video

Updated: Mar 3, 2026

Transcranial Pulse Stimulation for Alzheimer's Patients

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

Re-Engineering Alzheimer Clinical Trials: Global Alzheimer's Platform Network.

J Cummings¹, P Aisen², R Barton³

¹Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA.

The Journal of Prevention of Alzheimer'S Disease

|May 2, 2017

Summary

The Global Alzheimer Platform (GAP) initiative, including GAP-NET, aims to improve Alzheimer's disease (AD) clinical trials through standardized sites and efficient recruitment. This accelerates the development and availability of new AD treatments.

Keywords:

Alzheimer’s disease Global Alzheimer Platform certification clinical trials drug development drug discovery recruitment registry

More Related Videos

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

Published on: December 15, 2023

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Published on: May 28, 2017

Related Experiment Videos

Last Updated: Mar 3, 2026

Transcranial Pulse Stimulation for Alzheimer's Patients

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

Published on: December 15, 2023

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Published on: May 28, 2017

Area of Science:

Neuroscience
Clinical Trials
Drug Development

Background:

Alzheimer's disease (AD) drug development faces significant challenges including high costs, long timelines, and inefficiency.
Key areas needing improvement include trial site operations, clinical trial design, and patient recruitment.

Purpose of the Study:

To introduce the Global Alzheimer Platform (GAP) and its work streams designed to address inefficiencies in AD drug development.
To detail the GAP-NET initiative, focused on establishing a standardized network of qualified clinical trial sites.

Main Methods:

The GAP initiative comprises four work streams: registry-to-cohort recruitment, clinical trial site network construction (GAP-NET), adaptive trial design, and finance.
GAP-NET aims to create a network of continuously funded, highly qualified trial sites with established capabilities in clinical assessment, biomarkers, and imaging.
Standardized protocols, certified raters, and robust management systems will be implemented across the GAP-NET sites.

Main Results:

GAP-NET will conduct trials for academic and industry partners, leveraging collaborations with international initiatives like EPAD and CCNA for global reach.
The initiative is projected to enhance trial efficiency and quality, reduce redundancy, accelerate recruitment, and lower overall trial costs.
Value is provided to sites through stable funding and uniform training, to sponsors via reduced costs and timelines, and to patients through faster access to treatments.

Conclusions:

The GAP and GAP-NET initiatives represent a strategic approach to overcome critical barriers in Alzheimer's disease clinical research.
By standardizing trial site operations and improving recruitment, these programs aim to accelerate the delivery of effective therapies for AD patients.